Related Experiment Videos
When is medical prophylaxis cost-effective for recurrent calcium stones?
1Department of Surgery (Urology), University of Colorado Health Sciences Center, Denver, Colorado, USA.
Insights
Medical prophylaxis for recurrent calcium stones is not always cost-effective. The optimal strategy depends on individual stone recurrence rates and healthcare costs, requiring personalized cost-benefit analysis.
Area of Science:
- Urology
- Health Economics
- Nephrology
Background:
- Recurrent calcium stones necessitate preventive medical management.
- Modern treatments like lithotripsy and ureteroscopy raise questions about the cost-effectiveness of medical prophylaxis versus episodic treatment.
Purpose of the Study:
- To compare the costs of medical prophylaxis for recurrent calcium stones with the costs of managing acute stone episodes.
- To determine the stone recurrence rate at which medical prophylaxis and episodic treatment become cost-equivalent.
Main Methods:
- An international cost survey was conducted across 10 countries.
- Costs included emergency visits, imaging, and outpatient treatment for acute episodes.
- Prophylaxis costs involved metabolic evaluation, medication, follow-up visits, and annual imaging.
Main Results:
- Significant international variation in costs for both medical prophylaxis and acute stone episode management.
- The cost-equivalence point ranged from 0.3 to 4 stone episodes per year, depending on the country.
Conclusions:
- Medical management for a first stone episode is not cost-effective.
- Individualized cost-benefit analysis is crucial for determining the most cost-effective practice patterns for patients with recurrent calcium stone formation.
Purpose:
Medical management is generally recommended for recurrent calcium stones to prevent future episodes. However, in this era of extracorporeal shock wave lithotripsy and outpatient ureteroscopy it is not known whether medical prophylaxis is more cost-effective than treatment of recurrent stone episodes. The cost of medical prophylaxis was compared with the cost of clinically managing recurrent stone episodes, and the stone recurrence rate without prophylaxis (stone frequency) at which these 2 treatment approaches became cost equivalent was determined.
Materials And Methods:
An international cost survey was conducted in 10 countries to compare costs of medical prophylaxis and managing recurrent acute stone episodes. Costs of an acute stone episode included an emergency room visit, associated radiographic imaging to confirm diagnosis of a symptomatic stone and outpatient treatment of upper urinary tract stones that did not pass spontaneously. Costs of medical management included an initial limited metabolic evaluation, drug therapy, a followup office visit every 6 months that included a 24-hour urinalysis and radiographic imaging of the kidneys, ureters and bladder once a year.
Results:
Costs of medical prophylaxis and managing an acute stone episode varied significantly from country to country. The stone frequency at which costs of these management options became equivalent ranged from 0.3 to 4 stone episodes a year.
Conclusions:
Medical management of a first stone episode is not cost-effective. Cost analysis should be individualized for specific health care plans to determine which practice patterns are most cost-effective for a particular patient with recurrent calcium stone formation.